Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial.

Romera, Alvaro

Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial. [electronic resource] - The lancet. Gastroenterology & hepatology 12 2018 - 845-855 p. digital

Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

2468-1253

10.1016/S2468-1253(18)30269-3 doi


Adult
Aged
Antibodies--blood
Antineoplastic Agents, Immunological--adverse effects
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Area Under Curve
Bevacizumab--adverse effects
Biosimilar Pharmaceuticals--adverse effects
Camptothecin--analogs & derivatives
Colorectal Neoplasms--drug therapy
Female
Fluorouracil--therapeutic use
Humans
Intention to Treat Analysis
Leucovorin--therapeutic use
Male
Middle Aged
Neoplasm Metastasis
Organoplatinum Compounds--therapeutic use
Progression-Free Survival
Therapeutic Equivalency